

Carotid Artery Disease and What's Pertinent

JOSEPH A PAULISIN DO




Goal of treatment of carotid disease

- ▶ Identify those at risk of developing symptoms
- ▶ Prevent patients at risk from developing symptoms
- ▶ Prevent people who have already been symptomatic from developing further and worsening symptoms


Carotid Disease

- ▶ **Most common disease process: atherosclerosis**
 - ▶ **Other rare disease entities: Fibromuscular dysplasia, carotid artery aneurysms, dissections and carotid body tumors**
- ▶ **Increased risk:**
 - ▶ **Cigarette smoking, high cholesterol, diabetes, age, obesity, CKD**
- ▶ **Symptoms:**
 - ▶ **TIA (transient ischemic attacks) – precedes 15-20% of CVAs**
 - ▶ **Amaurosis fugax**
 - ▶ **<24 hrs**
 - ▶ **CVA (cerebrovascular accidents)**
 - ▶ **More than 24 hours**
 - ▶ **Syncope?**

Symptoms



- ▶ **Motor or sensory deficit contralateral to affected carotid artery**
- ▶ **Amaurosis ipsilateral to affected carotid artery**



Pathophysiology of carotid plaquing

- ▶ **At bifurcation of carotid**
 - ▶ **Where artery splits into two, high shear stress and tendency for stagnation of blood**
 - ▶ **Over time, an ulcer can form through the fibrous cap of the plaque.**
 - ▶ **Platelets then deposit within the ulcer**
 - ▶ **These platelets lead to more platelets**
 - ▶ **As blood flows into the ulcer, the platelets and other debris can embolize up the internal carotid and into the brain**
 - ▶ **Can cause a TIA, CVA or nothing**
 - ▶ **Transcranial doppler example**
- ▶ **Further study into morphology of plaque to identify high risk patients.**

Stroke

- ▶ 600,000 strokes per year in U.S.
- ▶ 150,000 deaths from stroke per year
- ▶ 3rd leading cause of death



Causes of stroke

- ▶ **Hemorrhagic (15%)**
- ▶ **Non-hemorrhagic (85%)**
 - ▶ **Cardioembolic**
 - ▶ **Afib, valvular disease**
 - ▶ **Large vessel disease 10-20%**
 - ▶ **Carotid artery atherosclerotic disease**
 - ▶ **Small vessel disease**
 - ▶ **Usually hypertension induced**
 - ▶ **Hematologic disorders**
 - ▶ **Polycythemia, hypercoagulable state**




Imaging of the Carotid arteries



▶ Ultrasound

- ▶ Least invasive, low risk
- ▶ Measure Peak systolic velocity and end diastolic velocity
 - ▶ Allows an estimate of percent stenosis
- ▶ Good screening tool



▶ CTA

- ▶ Tends to underestimate
- ▶ Helps delineate anatomical variations
 - ▶ High or low bifurcation
 - ▶ Aneurysmal/fmd and other rare entities
- ▶ Risk of contrast: allergy and renal impairment





CTA




Imaging of the Carotid arteries

- ▶ **MRA**
 - ▶ Tends to overestimate
 - ▶ Technology may be institutionally dependent
 - ▶ Risk of magnet: patient metal
 - ▶ Gadolinium toxicity
 - ▶ Nephrogenic systemic fibrosis
- ▶ **Digital Subtraction Angiography**
 - ▶ Most invasive
 - ▶ Less iv contrast
 - ▶ Gold standard
 - ▶ Risk of access site and stroke (0.1 percent)
 - ▶ Tie breaker
- ▶ **Rare tests PET/CT and Transcranial doppler (TCD)**



MRA and DSA



How do we identify people at risk of developing a stroke from carotid stenosis

- ▶ **History and physical**
 - ▶ **Carotid Bruit**
 - ▶ Low sensitivity and specificity
 - ▶ **Eye Exam**
 - ▶ Hollenhorst plaque
- ▶ **Screening Ultrasounds**
 - ▶ High rate of detection of disease in asymptomatic patients
 - ▶ Low yield if other risk factors not present
 - ▶ US Preventive Services Task force currently recommends in patients at high risk
- ▶ **People with potential symptoms**



Treatment of Carotid Stenosis

- ▶ **Asymptomatic vs Symptomatic**
 - ▶ same three options just when utilize is different
- ▶ **Best medical therapy**
 - ▶ Aspirin, Plavix and statins
 - ▶ Control risk factors
- ▶ **Surgery (revascularization)**
 - ▶ Carotid endarterectomy
- ▶ **Stenting (revascularization)**
 - ▶ Unless hospital/surgeon is in a trial, only approved in symptomatic patients



Indications for Revascularization



- ▶ Largely independent of method of revascularization
- ▶ Symptomatic disease
- ▶ Asymptomatic disease
- ▶ 3% rule (ACAS 2.3% stroke/death)
- ▶ We will ignore posterior fossa and external carotid disease today

Contraindications to Revascularization

- ▶ **Disabling stroke, especially with altered LOC**
- ▶ **Total occlusion**
- ▶ **Medical comorbidities**
- ▶ **Life expectancy too short to derive benefit**



Symptomatic Disease

- ▶ 70 – 99%
- ▶ NASCET 2 year follow up
 - ▶ 26% stroke risk in medical arm
 - ▶ 9% stroke risk in surgical arm




Symptomatic Disease

- ▶ 50 – 69%
- ▶ NASCET 5 year follow up
 - ▶ 22.7% stroke risk in medical arm
 - ▶ 15.7% stroke risk in surgical arm



Symptomatic Disease

- ▶ Symptoms within 120 days
- ▶ Increased risk reduction with greater degrees of stenosis
- ▶ Especially benefits males > 75
- ▶ There is benefit for women, but not as dramatic



Asymptomatic Disease



- ▶ > 60%
- ▶ ACAS 5 year follow up
 - ▶ 11% stroke risk in medical arm
 - ▶ 5.1% stroke risk in surgical arm



Asymptomatic Disease

- ▶ No increased risk reduction with greater degrees of stenosis
- ▶ Greatest benefits in patients < 65
- ▶ Lesser benefit in women
- ▶ Consider limiting to
 - ▶ > 80%
 - ▶ contralateral occlusion or high grade stenosis
 - ▶ ulcerated lesions

Anatomy



Endarterectomy vs. Stenting

- ▶ High-risk for endarterectomy – CMS criteria
- ▶ CEA vs. CAS trials



Anatomic High Risk for Endarterectomy

- ▶ **Anatomically inaccessible lesion**
- ▶ **Cervical immobility**
- ▶ **Prior neck dissection**
- ▶ **Tracheostomy**
- ▶ **Contralateral cranial nerve injury**
- ▶ **Radiation**
- ▶ **Contralateral occlusion**
- ▶ **Recurrent stenosis**



Medical High Risk for Endarterectomy

- ▶ COPD
- ▶ NYHA III or IV CHF
- ▶ EF < 30%
- ▶ Unstable angina
- ▶ Recent MI




Endarterectomy Outcomes

- ▶ **Symptomatic**
 - ▶ 0.6 – 1% death
 - ▶ 5 – 7% stroke/death
- ▶ **Asymptomatic**
 - ▶ 2.3% stroke/death



Endarterectomy Outcomes

- ▶ Cranial nerve injury: 4 – 7%
- ▶ Hemorrhage: 3%
- ▶ MI: 1 – 2.6%
- ▶ Hyperperfusion syndrome/intracranial hemorrhage: 1%
- ▶ Restenosis: 3 - 6%
- ▶ Infection: 0.3 – 0.8%



Stenting Outcomes

- ▶ **Randomized trials plagued by**
 - ▶ **bias**
 - ▶ **operator inexperience**
 - ▶ **aberrant CEA outcomes**
 - ▶ **nonstandardized EPD**
 - ▶ **angioplasty without stent**



Stenting Outcomes

Trial	CEA stroke/death	CAS stroke/death	CEA restenosis	CAS restenosis
CAVATAS 2001	9.9%	10%	10.5%	30.7%
SAPPHIRE 2004	20.1%	12.2%		
EVA-3S 2006	3.9%	9.6%		
SPACE 2006	6.3%	6.8%	4.6%	10.7%

Technical Aspects of Endarterectomy

- ▶ GA or regional
- ▶ Routine or selective shunting
- ▶ Monitoring
- ▶ Eversion or longitudinal endarterectomy
- ▶ ***Patch or no patch***



